Peptide Research Database

Access 7,487 peer-reviewed studies, clinical trials, and research papers on peptides. Filter by key research, study type, compound, and category. Direct links to full PubMed entries for comprehensive, evidence-based exploration.

Other
PMID: 43018634
2026 Nov 12

Discovery of Orally Effective Corydamine Derivatives Targeting Glutathione Metabolism to Sensitize Hepatocellular Carcinoma to Sorafenib.

This study found these findings propose a redox-targeting strategy to sensitize HCC to sorafenib and highlight 8g as a promising anti-HCC lead. Designed and synthesized a series of new corydamine derivatives and identified 8g as a lead compound with anti-HCC activity comparable to sorafenib.

An Z, Zou H, Sun Y, Deng X, Ping X, Li Z, Li Y, Hu Q, Long K, Zhang X, Peng Y, Mo H, Peng Y, Yang H, Jiang W, Luo Y, Wang Z, Zhuo L

Sorafenib offers limited benefit in hepatocellular carcinoma (HCC). In this study, we designed and synthesized a series of novel corydamine derivatives and identified 8g as a lead compound with anti-HCC activity comparable to sorafenib. Mechanistic studies suggest that 8g targets glutathione reductase (GR), disrupting glutathione metabolism and NADPH homeostasis and weakening tumor redox defenses. Notably, the combination of 8g and sorafenib markedly enhanced ROS generation, inhibited HCC cell migration and invasion, and induced G2/M arrest and apoptosis, demonstrating strong synergistic anticancer activity. In addition, 8g showed favorable druggability, including good metabolic stability in human liver microsomes (T1/2 > 5 h), low hERG inhibition (IC50 > 50 μM), and high oral bioavailability (84.9%). In a Huh7 xenograft model, the combination achieved 61.0% tumor growth inhibition, significantly outperforming sorafenib alone (29.7%). These findings propose a redox-targeting strategy to sensitize HCC to sorafenib and highlight 8g as a promising anti-HCC lead.

Journal of medicinal chemistry
Other
PMID: 43020428
2026 Nov 12

Letter to Editor regarding 'Higher maternal body mass index is associated with increased oxytocin requirements during induction of labor: a population-based cohort study'.

Postrano DLMC

American journal of obstetrics & gynecology MFM
Case Report
DOI
2026-11-11

Reversal of Heart Age in Adults with Obesity After Initiation of Semaglutide Detected by Serial Electrocardiography

In a case report, taken together, relative ECG age fell after initiation of semaglutide or tirzepatide but not meaningfully after bariatric surgery, despite the exact opposite magnitude of weight loss achieved, suggesting electrocardiographic heart age may reflect a hitherto unappreciated, weight-loss-independent dimension of GLP-1 pharmacology not associated with currently monitored standard clinical heart health.

Murugadoss K, Venkatakrishnan A, Soundararajan V.

Semaglutide lowers cardiovascular events in adults with obesity, but whether it slows biological aging of the heart, and whether any such effect is explained by weight loss, is unknown. We developed and validated a hybrid convolutional and transformer deep learning neural network model that estimates age from a routine 12-lead electrocardiogram (ECG), using a training set of 1,019,079 adult ECGs and a held-out test set of 99,994 adult ECGs. The model estimated age with a mean absolute error (MAE) of 5.80 years and explained 82% of the variation in age (R² 0.817), the best reported performance for any ECG age model to date. On an independent validation population of 802,331 patients, the model achieved an MAE of 6.92 years and R² of 0.751. We defined relative ECG age as ECG-predicted age minus chronologic age. We then compared its change from the last ECG before treatment between new users of semaglutide and patients undergoing bariatric surgery, and between patients who initiated semaglutide versus tirzepatide with at least 6 months on treatment. Patients were matched 1:1 on sex, age and year of treatment start, and on a propensity score built from baseline BMI, weight, ECG age, number of prior ECGs, eight comorbidities and race (2,549 semaglutide-bariatric surgery pairs; 950 semaglutide-tirzepatide pairs). At 12 months, bariatric surgery patients had lost an average of 25.6% of their body weight whereas semaglutide patients lost only 4.8% of body weight. However, relative ECG age on semaglutide decreased significantly below baseline at every window from 6 months onward, by −0.73 years (95% confidence interval [CI] −1.29 to −0.17) at 12 months and −1.23 years (95% CI −2.04 to −0.42) at 15 months, whereas relative ECG age did not significantly change at any evaluated time point after bariatric surgery. The difference in relative ECG age change (semaglutide minus bariatric surgery) was a statistically significant −1.28 years (95% CI −2.48 to −0.09; P=0.035; 304 vs 148 patients) at 12 months and −1.86 years (95% CI −3.19 to −0.53; P=0.006; 179 vs 95) at 21 months. Compared to tirzepatide, which was also associated with more average weight loss than semaglutide (−11.2% versus −7.1% at 12 months), the largest difference in relative ECG age (semaglutide minus tirzepatide) was −1.19 years at 15 months and was not significant (95% CI −3.27 to +0.88, P=0.26). Over 5 years, mortality was lower in semaglutide patients than in their matched bariatric surgery patients (hazard ratio [HR] 0.44, 95% CI 0.34 to 0.59), and this difference in mortality accounted for the lower rate of major adverse cardiovascular events (MACE; death, heart attack or stroke) on semaglutide (HR 0.73, 95% CI 0.58 to 0.91). Taken together, relative ECG age fell after initiation of semaglutide or tirzepatide but not meaningfully after bariatric surgery, despite the exact opposite magnitude of weight loss achieved, suggesting electrocardiographic heart age may reflect a hitherto unappreciated, weight-loss-independent dimension of GLP-1 pharmacology not associated with currently monitored standard clinical cardiovascular outcomes.

Case Report
DOI
2026-11-11

An Unusual Case of Non-classical 21-Hydroxylase Deficiency Presenting with Hypercortisolemia and Hyperandrogenemia: A Case Report

In a case report, clinicians should maintain heightened awareness of this atypical presentation to avoid misdiagnosis.

Qiu Y, Zhang L, Pan Y, Yao J.

Abstract Background Non-classical 21-hydroxylase deficiency (NC-21OHD) typically presents with hyperandrogenemia and low-to-normal cortisol levels. However, elevated cortisol levels are exceedingly rare and may lead to diagnostic confusion with Cushing's syndrome. Case Presentation: We report a 25-year-old woman who presented with a three-month history of menstrual irregularities. Physical examination revealed a full-moon face, hirsutism, male-pattern pubic hair distribution, and clitoral hypertrophy. Laboratory investigations demonstrated hypercortisolemia (serum cortisol: 27.98 µg/dL at 8 AM; urinary free cortisol: 264.38 µg/24h) and hyperandrogenemia (testosterone: 1.25 ng/mL; DHEA-S: 1025 µg/dL). Enhanced computed tomography revealed bilateral adrenal thickening. Although these findings initially suggested Cushing's syndrome, low-dose dexamethasone suppression testing markedly suppressed both cortisol (15.88 → 0.63 µg/dL) and testosterone (1.25 → 0.63 ng/mL), effectively excluding Cushing's syndrome and indicating an adrenal source of hyperandrogenemia. Notably, basal 17-hydroxyprogesterone (17-OHP) was within the normal range (0.77 ng/mL), but cosyntropin stimulation elevated 17-OHP to 11.54 ng/mL. Subsequent genetic testing confirmed CYP21A2 mutations, establishing the diagnosis of NC-21OHD. Glucocorticoid therapy with prednisone (2.5 mg nightly) normalized menstrual cycles and androgen levels within one month, with follow-up imaging showing significant adrenal size reduction at six months. Conclusions This case highlights that hypercortisolemia can occur in NC-21OHD and may coexist with features mimicking Cushing's syndrome. The combination of low-dose dexamethasone suppression testing—to simultaneously exclude Cushing's syndrome and confirm adrenal-derived hyperandrogenemia—followed by ACTH stimulation testing and genetic confirmation, represents a critical diagnostic pathway. Clinicians should maintain heightened awareness of this atypical presentation to avoid misdiagnosis.

Clinical Trial
Landmark Study
PMID: 43013292
2026 Nov 11

First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.

In a randomized trial, oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo, highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and mortality in this high-risk population.

Marx N, Deanfield JE, Mulvagh SL, Videmark A, van Bemmel T, Buse JB, Davicevic-Elez Z, Engelmann MDM, Haluzik M, Hovingh GK, Inzucchi SE, Mann JFE, Mathieu C, Musinga D, Pop-Busui R, Poulter NR, Rea RR, Roman G, Saraiva JFK, Watada H, McGuire DK

In the Semaglutide Cardiovascular Outcomes Trial (SOUL), oral semaglutide reduced the risk of a first 3-point major adverse cardiovascular event (3-P MACE; including nonfatal myocardial infarction, nonfatal stroke, and cardiovascular [CV] death). Total event analyses, assessing both first and subsequent events, can contribute to a better understanding of the impact of interventions on the total burden of disease; however, the effects of oral semaglutide on subsequent events are unknown. To evaluate the effect of oral semaglutide vs placebo on total 3-P MACE. This was a prespecified secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, conducted from June 2019 to September 2024 with a median (IQR) follow-up of 49.5 (44.0-54.9) months at 444 centers in 33 countries. Participants had type 2 diabetes and atherosclerotic CV disease and/or chronic kidney disease. Data were analyzed from December 2024 to August 2025. Once-daily oral semaglutide (maximal dose 14 mg) or placebo, in addition standard of care. Occurrence of total (first and subsequent) 3-P MACE. Overall, 9650 participants (median [IQR] age, 66.0 [61.0-72.0] years; 6860 [71.1%] male) were randomized 1:1. In the oral semaglutide group, fewer first and subsequent 3-P MACE occurred (683 total; 579 first and 104 subsequent events) compared with placebo (791 total; 668 first and 123 subsequent events) (mean ratio, 0.86; 95% CI, 0.76-0.97; P = .01). For the end point of 3-P MACE plus non-CV death, there were 138 fewer total events with oral semaglutide (910 events) compared with placebo (1048 events) (mean ratio, 0.87; 95% CI, 0.79-0.95; P = .004). As previously reported, adverse events led to treatment discontinuation in 749 (15.5%) and 559 (11.6%) participants receiving oral semaglutide and placebo, respectively. Oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo, highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and mortality in this high-risk population. ClinicalTrials.gov Identifier: NCT03914326.

JAMA cardiology
Animal Study
Notable
PMID: 43015813
2026 Nov 11

Oxytocinergic neurons in the paraventricular nucleus mediate the analgesic effect of electroacupuncture in inflammatory pain.

In a mouse study, our findings highlight the critical role of PVN oxytocinergic brain cells in mediating the frequency-specific analgesic effects of EA, which provide important evidence for parameter selection in clinical EA treatment for pain. Aimed to identify the central neural projections responsible for EA-induced analgesia and to investigate the mechanisms underlying its frequency-specific effects.

Liu J, Wang X, Han Q, Chen Y, Zheng B, Yang W, Wang B, Ma Y, Sun J, Zheng Y

Electroacupuncture (EA) is a well-established and effective analgesic intervention, particularly for inflammatory pain; however, the analgesic effect of EA is closely related to the stimulation frequency, amplitude, and acupoint. The underlying neural mechanisms remain incompletely understood. This study aimed to identify the central neural projections responsible for EA-induced analgesia and to investigate the mechanisms underlying its frequency-specific effects. In this study, we utilized a mouse model of carrageenan (CGN)-induced inflammatory pain to explore the analgesic effects of EA. In vivo fiber photometry and immunofluorescence were employed to monitor the activity of oxytocinergic neurons in the paraventricular nucleus (PVN). The role of neuronal activity in EA-induced analgesia was assessed through chemogenetic and pharmacological approaches. We demonstrated that specific activation of PVN oxytocinergic neurons significantly alleviated pain behaviors in the inflammatory pain model mice. EA stimulation of the Stomach meridian 36 (ST36) activated PVN oxytocinergic neurons and exerted an antinociceptive effect in a frequency-dependent manner. Specifically, lower frequency EA stimulation induced more significant PVN oxytocinergic neuronal activity and analgesic effect, while higher frequency EA stimulation did not show significant neuronal activation or pain relief. Chemogenetic silencing of PVN oxytocinergic neurons completely abolished EA-induced analgesia. Additionally, we identified that oxytocinergic projections from the PVN to the arcuate nucleus (ARC) were activated only under lower frequency EA stimulation, while higher frequency EA stimulation failed to exert this effect. What's more, locally blocking the target of oxytocin in the ARC significantly attenuated the analgesic effect of EA. Our findings highlight the critical role of PVN oxytocinergic neurons in mediating the frequency-specific analgesic effects of EA, which provide important evidence for parameter selection in clinical EA treatment for pain.

Chinese medicine
Other
PMID: 43015368
2026 Nov 11

Rare GLP1R variants attenuate weight loss with semaglutide but not tirzepatide.

This study found our study demonstrates that rare GLP1R variants affect the response to semaglutide but not to tirzepatide.

Levy ME, Schiabor Barrett KM, Telis N, Lagarde WH, Phatak PD, Maher JF, Haldeman-Englert C, Grzymski JJ, Stoller D, Sturm AC, Judge DP, Chahal CAA, Renbarger JL, Chapman CN, Powell SF, Olson DA, Shefchek K, McEwen LM, Washington NL, Lee W, Cirulli ET

Weight loss with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is heterogeneous across individuals, yet the genetic causes of this variation are not fully known. We integrated exome sequencing data with electronic health records within the Helix Research Network (n = 351,818). Here, we show that, among 13,725 GLP-1RA-treated adults, carriers of rare damaging GLP1R variants lose less weight with semaglutide than matched non-carriers but achieve a near-normal tirzepatide response. Carriers of rare variants in GIPR, which encodes the glucose-dependent insulinotropic polypeptide receptor, the second target of tirzepatide, also achieve normal weight loss responses. Our study demonstrates that rare GLP1R variants affect the response to semaglutide but not to tirzepatide.

Nature metabolism
Other
PMID: 43012889
2026 Nov 11

Follow-up discrepancies in a TriNetX-based comparison of preoperative tirzepatide or semaglutide use and postoperative total hip/knee arthroplasty outcomes.

Wang J

European journal of orthopaedic surgery & traumatology : orthopedie traumatologie
Review
Notable
PMID: 43012562
2026 Nov 11

Gut-hormone receptor systems in the eye: Pharmacological, local and putative endocrine signalling.

In a research review, overall, current evidence supports pharmacological and local ocular peptide-receptor signalling, whereas direct physiological endocrine communication between the gut and eye remains unproven.

Wang Z, Zich LW, Li Y, Liu Y

The neural retina has traditionally been viewed as a downstream target of systemic metabolic disease, yet experimental and clinical evidence suggests that ocular tissues may also respond directly to peptide-hormone signalling. This review critically examines gut-hormone-related receptor systems in the eye across three biologically distinct evidence streams: endogenous circulating gut peptides, pharmacological receptor agonism, and locally synthesised ocular peptides. Physiological retinal access of native gut peptides remains poorly characterised, while receptor localisation is highly dependent on species and detection methodology. Mechanistic evidence is strongest for pharmacological GLP-1 receptor activation and local NPY and ghrelin systems, particularly in relation to neuroprotection, immunomodulation, metabolic and oxidative homeostasis, and neurovascular regulation. Human evidence remains disease-specific: diabetic retinopathy findings vary with glycaemic trajectory and endpoint definition; age-related macular degeneration associations are heterogeneous; glaucoma studies suggest a possible reduction in incidence without establishing protection against progression; and dry-eye evidence remains preliminary. Semaglutide also carries a regulatory safety signal for non-arteritic anterior ischaemic optic neuropathy. Future research should establish physiological ligand access and receptor engagement, validate ocular receptor localisation, characterise retinal and optic-nerve-head microvascular responses, and incorporate prospective ophthalmic phenotyping into metabolic-drug trials. Overall, current evidence supports pharmacological and local ocular peptide-receptor signalling, whereas direct physiological endocrine communication between the gut and eye remains unproven.

European journal of ophthalmology
Other
PMID: 43013976
2026 Nov 11

Sedated dental procedures increase endogenous plasma ACTH concentration in horses in the fall.

This study found it is unknown whether results would differ in horses with PPID.

McEnaney KR, Bertin FR, Wefel S, Bianco AW

To measure the effect of sedation with detomidine and butorphanol and a routine dental procedure on endogenous plasma ACTH concentrations of healthy older horses and to determine how long this effect, if any, persists to improve testing recommendations for pituitary pars intermedia dysfunction (PPID). It was hypothesized that a sedated dental procedure would not significantly affect endogenous plasma ACTH concentrations as compared to baseline in healthy adult horses. This prospective crossover study included 12 healthy mares of various breeds, aged 8 to 20 years, from the university herd with no clinical signs or history of PPID. Horses were sampled during both the spring (February 2025) and fall (September/October 2025) undergoing either a sedated oral examination or dental equilibration in alternating fall and spring periods. Blood samples were collected to quantify plasma ACTH concentrations from 0 minutes to 72 hours following sedation. There was a significant effect of season but not procedure on plasma ACTH concentration. In the fall, sedation was significantly associated with increased plasma ACTH concentrations; however, the effect was no longer significant after 15 minutes. There was no significant effect of sedation and dentistry detected on plasma ACTH concentration in the spring. Season and timing of sample collection following sedation influenced plasma ACTH concentration. PPID sampling can be performed 15 minutes after sedation in the fall. It is unknown whether results would differ in horses with PPID.

Journal of the American Veterinary Medical Association